Remifentanil Preconditioning Reduces Postischemic Myocardial Infarction and Improves Left Ventricular Performance via Activation of the Janus Activated Kinase-2/Signal Transducers and Activators of Transcription-3 Signal Pathway and Subsequent Inhibition of Glycogen Synthase Kinase-3β in Rats

Critical Care Medicine

Volumn 44, Issue 3, 2016, Pages e131-e145

  Qiao, Shigang ^a,b   Mao, Xiaowen ^a,c   Wang, Yan ^a   Lei, Shaoqing ^a   Liu, Yanan ^a   Wang, Tingting ^a   Wong, Gordon T ^a   Cheung, Chi Wai ^a   Xia, Zhengyuan ^a,c,d   Irwin, Michael G ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b SOOCHOW UNIVERSITY   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Apoptosis; glycogen synthase kinase; Janus activated kinase; myocardial ischemia injury; remifentanil

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; CREATINE KINASE MB; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCOGEN SYNTHASE KINASE 3BETA; JANUS KINASE 2; LACTATE DEHYDROGENASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REMIFENTANIL; STAT3 PROTEIN; WORTMANNIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; PIPERIDINE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL HYPOXIA; CONTROLLED STUDY; CORONARY ARTERY OCCLUSION; ENZYME ACTIVATION; ENZYME INHIBITION; EX VIVO STUDY; GENE SILENCING; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEART PROTECTION; HEART RATE; HEART STROKE VOLUME; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIC PRECONDITIONING; ISOLATED HEART; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REOXYGENATION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE CELL; DRUG EFFECTS; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PHOSPHORYLATION; PHYSIOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT;

ANIMALS; GLYCOGEN SYNTHASE KINASE 3; ISCHEMIC PRECONDITIONING; JANUS KINASE 2; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; VENTRICULAR FUNCTION, LEFT;

EID: 84959194767     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000001350     Document Type: Article

References (56)

1. Kim HS, Cho JE, Hong SW, et al: Remifentanil protects myocardium through activation of anti-apoptotic pathways of survival in ischemiareperfused rat heart. Physiol Res 2010; 59:347-356
2. Zhang Y, Irwin MG, Wong TM: Remifentanil preconditioning protects against ischemic injury in the intact rat heart. Anesthesiology 2004; 101:918-923
3. Zhang Y, Irwin MG, Wong TM, et al: Remifentanil preconditioning confers cardioprotection via cardiac kappa-and delta-opioid receptors. Anesthesiology 2005; 102:371-378
4. Chun KJ, Park YH, Kim JS, et al: Comparison of 5 different remifentanil strategies against myocardial ischemia-reperfusion injury. J Cardiothorac Vasc Anesth 2011; 25:926-930
5. Wong GT, Huang Z, Ji S, et al: Remifentanil reduces the release of biochemical markers of myocardial damage after coronary artery bypass surgery: A randomized trial. J Cardiothorac Vasc Anesth 2010; 24:790-796
6. Hausenloy DJ, Mocanu MM, Yellon DM: Cross-talk between the survival kinases during early reperfusion: Its contribution to ischemic preconditioning. Cardiovasc Res 2004; 63:305-312
7. Hu Y, Chen X, Pan TT, et al: Cardioprotection induced by hydrogen sulfide preconditioning involves activation of ERK and PI3K/Akt pathways. Pflugers Arch 2008; 455:607-616
8. Milano G, Abruzzo PM, Bolotta A, et al: Impact of the phosphatidylinositide 3-kinase signaling pathway on the cardioprotection induced by intermittent hypoxia. PLoS One 2013; 8:e76659
9. Xuan YT, Guo Y, Han H, et al: An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci USA 2001; 98:9050-9055
10. Gross ER, Hsu AK, Gross GJ: The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta. Am J Physiol Heart Circ Physiol 2006; 291:H827-H834
11. Lecour S: Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway J Mol Cell Cardiol 2009; 47:32-40
12. Lochner A, Huisamen B, Nduhirabandi F: Cardioprotective effect of melatonin against ischaemia/reperfusion damage. Front Biosci (Elite Ed) 2013; 5:305-315
13. Kim JM, Jang YH, Kim J: Morphine and remifentanil-induced cardioprotection: Its experimental and clinical outcomes. Korean J Anesthesiol 2011; 61:358-366
14. Hu X, Xie C, He S, et al: Remifentanil postconditioning improves global cerebral ischemia-induced spatial learning and memory deficit in rats via inhibition of neuronal apoptosis through the PI3K signaling pathway. Neurol Sci 2013; 34:1955-1962
15. Green DR, Reed JC: Mitochondria and apoptosis. Science 1998; 281:1309-1312
16. Watcharasit P, Bijur GN, Song L, et al: Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem 2003; 278:48872-48879
17. Crompton M, Costi A: A heart mitochondrial Ca2(+)-dependent pore of possible relevance to re-perfusion-induced injury. Evidence that ADP facilitates pore interconversion between the closed and open states. Biochem J 1990; 266:33-39
18. Halestrap AP, Brenner C: The adenine nucleotide translocase: A central component of the mitochondrial permeability transition pore and key player in cell death. Curr Med Chem 2003; 10:1507-1525
19. Javadov SA, Clarke S, Das M, et al: Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol 2003; 549:513-524
20. Juhaszova M, Zorov DB, Kim SH, et al: Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 2004; 113: 1535-1549
21. Chipuk JE, Kuwana T, Bouchier-Hayes L, et al: Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303:1010-1014
22. Wang CY, Yang TT, Chen CL, et al: Reactive oxygen species-regulated glycogen synthase kinase-3 activation contributes to all-trans retinoic acid-induced apoptosis in granulocyte-differentiated HL60 cells. Biochem Pharmacol 2014; 88:86-94
23. Zhang Q, Fu H, Zhang H, et al: Hydrogen sulfide preconditioning protects rat liver against ischemia/reperfusion injury by activating Akt-GSK-3 signaling and inhibiting mitochondrial permeability transition. PLoS One 2013; 8:e74422
24. Routhu KV, Tsopanoglou NE, Strande JL: Parstatin(1-26): The putative signal peptide of protease-activated receptor 1 confers potent protection from myocardial ischemia-reperfusion injury. J Pharmacol Exp Ther 2010; 332:898-905
25. Wang C, Xie H, Liu X, et al: Role of nuclear factor-B in volatile anaesthetic preconditioning with sevoflurane during myocardial ischaemia/reperfusion. Eur J Anaesthesiol 2010; 27:747-756
26. Mao X, Wang T, Liu Y, et al: N-acetylcysteine and allopurinol confer synergy in attenuating myocardial ischemia injury via restoring HIF-1/HO-1 signaling in diabetic rats. PLoS One 2013; 8:e68949
27. Li H, Liu Z, Wang J, et al: Susceptibility to myocardial ischemia reperfusion injury at early stage of type 1 diabetes in rats. Cardiovasc Diabetol 2013; 12:133
28. Xu J, Li H, Irwin MG, et al: Propofol ameliorates hyperglycemiainduced cardiac hypertrophy and dysfunction via heme oxygenase-1/signal transducer and activator of transcription 3 signaling pathway in rats. Crit Care Med 2014; 42:e583-e594
29. Fiordaliso F, Bianchi R, Staszewsky L, et al: Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. J Mol Cell Cardiol 2004; 37:959-968
30. Heusch G, Musiolik J, Gedik N, et al: Mitochondrial STAT3 activation and cardioprotection by ischemic postconditioning in pigs with regional myocardial ischemia/reperfusion. Circ Res 2011; 109:1302-1308
31. Wang T, Qiao S, Lei S, et al: N-acetylcysteine and allopurinol synergistically enhance cardiac adiponectin content and reduce myocardial reperfusion injury in diabetic rats. PLoS One 2011; 6:e23967
32. Huang JP, Huang SS, Deng JY, et al: Insulin and resveratrol act synergistically, preventing cardiac dysfunction in diabetes, but the advantage of resveratrol in diabetics with acute heart attack is antagonized by insulin. Free Radic Biol Med 2010; 49:1710-1721
33. Viola HM, Jordan MC, Roos KP, et al: Decreased myocardial injury and improved contractility after administration of a peptide derived against the alpha-interacting domain of the L-type calcium channel. J Am Heart Assoc 2014; 3:e000961
34. Lei S, Li H, Xu J, et al: Hyperglycemia-induced protein kinase C 2 activation induces diastolic cardiac dysfunction in diabetic rats by impairing caveolin-3 expression and Akt/eNOS signaling. Diabetes 2013; 62:2318-2328
35. Salem R, Denault AY, Couture P, et al: Left ventricular end-diastolic pressure is a predictor of mortality in cardiac surgery independently of left ventricular ejection fraction. Br J Anaesth 2006; 97:292-297
36. Takemura G, Fujiwara H: Role of apoptosis in remodeling after myocardial infarction. Pharmacol Ther 2004; 104:1-16
37. Gross GJ: Role of opioids in acute and delayed preconditioning. J Mol Cell Cardiol 2003; 35:709-718
38. Hausenloy DJ, Yellon DM: Preconditioning and postconditioning: United at reperfusion. Pharmacol Ther 2007; 116:173-191
39. Zatta AJ, Kin H, Yoshishige D, et al: Evidence that cardioprotection by postconditioning involves preservation of myocardial opioid content and selective opioid receptor activation. Am J Physiol Heart Circ Physiol 2008; 294:H1444-H1451
40. Amour J, Brzezinska AK, Weihrauch D, et al: Role of heat shock protein 90 and endothelial nitric oxide synthase during early anesthetic and ischemic preconditioning. Anesthesiology 2009; 110:317-325
41. Förster K, Kuno A, Solenkova N, et al: The delta-opioid receptor agonist DADLE at reperfusion protects the heart through activation of pro-survival kinases via EGF receptor transactivation. Am J Physiol Heart Circ Physiol 2007; 293:H1604-H1608
42. Lo RK, Wong YH: Signal transducer and activator of transcription 3 activation by the delta-opioid receptor via Galpha14 involves multiple intermediates. Mol Pharmacol 2004; 65:1427-1439
43. Ballesta JJ, Cremades J, Rodríguez-Munõz M, et al: Sensitivity to-opioid receptor-mediated anti-nociception is determined by crossregulation between-and-opioid receptors at supraspinal level. Br J Pharmacol 2012; 166:309-326
44. Negoro S, Kunisada K, Fujio Y, et al: Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. Circulation 2001; 104:979-981
45. Negoro S, Kunisada K, Tone E, et al: Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc Res 2000; 47:797-805
46. Mao XW, Green LM, Mekonnen T, et al: Gene expression analysis of oxidative stress and apoptosis in proton-irradiated rat retina. In Vivo 2010; 24:425-430
47. Juhaszova M, Zorov DB, Yaniv Y, et al: Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res 2009; 104:1240-1252
48. Mei B, Wang T, Wang Y, et al: High dose remifentanil increases myocardial oxidative stress and compromises remifentanil infarct-sparing effects in rats. Eur J Pharmacol 2013; 718:484-492
49. Fan WJ, Genade S, Genis A, et al: Dexamethasone-induced cardioprotection: A role for the phosphatase MKP-1 Life Sci 2009; 84:838-846
50. Fan WJ, van Vuuren D, Genade S, et al: Kinases and phosphatases in ischaemic preconditioning: A re-evaluation. Basic Res Cardiol 2010; 105:495-511
51. Ovize M, Przyklenk K, Hale SL, et al: Preconditioning does not attenuate myocardial stunning. Circulation 1992; 85:2247-2254
52. Mosca SM, Gelpi RJ, Milei J, et al: Is stunning prevented by ischemic preconditioning Mol Cell Biochem 1998; 186:123-129
53. Kloner RA, Jennings RB: Consequences of brief ischemia: Stunning, preconditioning, and their clinical implications: Part 2. Circulation 2001; 104:3158-3167
54. Hoole SP, Khan SN, White PA, et al: Remote ischaemic pre-conditioning does not attenuate ischaemic left ventricular dysfunction in humans. Eur J Heart Fail 2009; 11:497-505
55. Sánchez JA, Rodríguez-Sinovas A, Barba I, et al: Activation of RISK and SAFE pathways is not involved in the effects of Cx43 deficiency on tolerance to ischemia-reperfusion injury and preconditioning protection. Basic Res Cardiol 2013; 108:351
56. Zhang QY, Wang W, Shi QX, et al: Antiarrhythmic effect mediated by-opioid receptor is associated with Cx43 stabilization. Crit Care Med 2010; 38:2365-2376